Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Lowers PT on Tornier on 4Q12 Results

Related TRNX
Benzinga's Top Upgrades, Downgrades For April 11, 2017
Integra LifeSciences to Acquire Total Ankle Replacement and Silastic Toe Replacement Product Portfolios from Tornier N.V.; Amount of Cash Payment Not Disclosed

In a report published Friday, BMO Capital Markets reiterated its Outperform rating on Tornier (NASDAQ: TRNX), but slightly lowered its price target from $23.00 to $22.00.

BMO Capital Markets noted, “TRNX announced 4Q12 results, provided reasonable 2013 guidance, and announced that David Mowry was appointed the permanent CEO (as we had anticipated). In the 4Q12, revenue of $79.0 million (up 14.5%, up 16% ex-fx, up 4.4% organic), included Upper Extremity and Trauma sales of $45.8 million (up 5.5%; up 6.4% ex-fx), Lower Extremity and Trauma sales of $6.8 million (down 3.4%, down 2.6% ex-fx), OrthoHelix sales of $8 million, Sports Medicine and Biologics sales of $4.2 million (up 3.8%; up 4.8% ex-fx), and Large Joints and Other sales of $14.3 million (down 2.1%; up 1.7% ex-fx). Adjusted EBITDA of $11.0 million bested the consensus' $9.9 million. EPS of negative $0.02 compares to the consensus' loss of $0.06.”

Tornier closed on Thursday at $16.30.

Latest Ratings for TRNX

May 2015Northland SecuritiesInitiates Coverage onMarket Perform
Nov 2014BarclaysMaintainsOverweight
Nov 2014PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for TRNX
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings


Related Articles (TRNX)

View Comments and Join the Discussion!

Partner Center